Skip to main navigation
Skip to search
Skip to main content
Search All UT System Experts
University of Texas Southwestern Medical Center Home
Home
Profiles
Research units
Equipment
Research output
Search by expertise, name or affiliation
Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
DAPA-CKD Investigators
Internal Medicine
Clinical Sciences
Nephrology
Research output
:
Contribution to journal
›
Article
›
peer-review
156
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Rationale and protocol of the Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol
100%
Chronic Renal Insufficiency
58%
Randomized Controlled Trials
43%
Sodium-Glucose Transporter 2 Inhibitors
34%
Symporters
32%
Glomerular Filtration Rate
22%
Kidney
17%
Albumins
13%
Type 2 Diabetes Mellitus
12%
Placebos
11%
Maximum Tolerated Dose
9%
Renin-Angiotensin System
8%
Risk Reduction Behavior
8%
Psychological Power
7%
Chronic Kidney Failure
7%
Creatinine
6%
Cardiovascular Diseases
5%
Guidelines
5%
Therapeutics
1%